Cargando…
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we explored factors that may lead to tivantinib resistance, especially in regards to its interaction with ATP-bind...
Autores principales: | Wu, Zhuo-Xun, Yang, Yuqi, Teng, Qiu-Xu, Wang, Jing-Quan, Lei, Zi-Ning, Wang, Jing-Qiu, Lusvarghi, Sabrina, Ambudkar, Suresh V., Yang, Dong-Hua, Chen, Zhe-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017082/ https://www.ncbi.nlm.nih.gov/pubmed/31940916 http://dx.doi.org/10.3390/cancers12010186 |
Ejemplares similares
-
OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Yang, Yuqi, et al.
Publicado: (2021) -
Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro
por: Yang, Yuqi, et al.
Publicado: (2020) -
PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study
por: Yang, Yuqi, et al.
Publicado: (2022) -
MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022) -
BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance
por: Ashar, Yunali V., et al.
Publicado: (2020)